Other Studies

Do you have a diagnosis of Ulcerative Colitis, with signs and symptoms consistent with UC for at least 3 months?

Have you been diagnosed with moderate to severely active UC disease activity?

If so, you may be eligible to participate in a clinical trial that is exploring the safety and efficacy of an open-label treatment of FDA approved Zeposia (Ozanimod) in participants with Moderate to severe Ulcerative Colitis. 

All subjects will undergo a screening colonoscopy for confirmation diagnoses. With a second colonoscopy mid-treatment at week 12 (Cohort 1) or/ week 26 (Cohort 2). 

There will be two arms for participants:

• Cohort 1: Participants with moderate to severely active UC who have not been exposed to biologics or immunomodulators for the treatment of UC (ie, advanced therapy-naïve).
• Cohort 2: Participants with moderate to severely active UC who have been exposed to a single mechanism of action of biologics for the treatment of UC (ie, advanced therapy-exposed).

Subjects will complete a screening period which may take up to 28 days. Followed by treatment with Zeposia for two years. A post-treatment follow-up (at 84 days) will complete participation. 

All study related procedures and office visits, along with study treatment will be covered under the study with no cost to you as a study participant. 

This trial can be further reviewed on https://clinicaltrials.gov/ct2/show/NCT05369832  

Other important readings: 

https://www.zeposia.com/ulcerative-colitis/ 

https://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-Zeposia-ozanimod-an-Oral-Treatment-for-Adults-with-Moderately-to-Severely-Active-Ulcerative-Colitis1/default.aspx  

See if you qualify by asking your doctor and calling : 727-786-0017 or contacting the research department at Advanced Gastroenterology Associates, LLC  727-216-0768.